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The cytotoxic potential of rabbit peripheral blood monocytes and alveolar macrophages in 
antibody-dependent cellular cytotoxicity (ADCC) toward both erytbrocyte (RB&) and tu- 
mor cell (CEM T-lymphoblast) targets was examined. ADCC was measured in a 4-hr “Cr- 
release assay. Alveolar macrophages were more efficient at killing the tumor cell targets 
(optimally sensitized with rabbit antisera) than monocytes at similar effector cell/target cell 
(E/T) ratios. Tumor cell targets sensitized with seven different antisera (anti-CEM) were 
lysed by alveolar macrophages but not by the monocytes. In marked contrast, the monocytes 
were more effective at lysing the sensitized erythrocyte target cells. The degree of cytolysis 
of RBCox and CEM was dependent on the E/T ratio and the degree of sensitization of these 
target cells. It was demonstrated that the effector cell selectivity in ADCC was directly related 
to their ability or inability to bind the sensitized target cells as determined by Fc-receptor 
rosette formation. The transition from monocyte to macrophage may, therefore, have resulted 
in an alteration in the criteria necessary for Fc-receptor binding to antibody-sensitized target 
cells and subsequent ADCC. 
INTRODUCTION 
Peripheral blood monocytes are the circulating precursors of the tissue-bound 
macrophages. Both cell populations are directly involved in antigen processing and 
clearance, and play an active role in the regulation of the immune response. The 
cells are derived from pluripotent stem cells generated in the bone marrow ( 1, 2). 
Although monocytes and macrophages may have unique functional characteristics, 
they share certain membrane receptors including the receptor for C3b (3, 4) and 
for the Fc portion of IgG (5-8). Both cell populations have been shown to be 
capable of binding soluble immune complexes and antibody-sensitized erythrocytes 
(EA’) (6-9), and have been shown to effectively lyse EA in antibody-dependent 
cellular cytotoxicity ( ADCC) (( lo- 13); as reviewed in (14- 16)). More recently, 
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’ Abbreviations used: ADCC, antibody-dependent cellular cytotoxicity; CEM, human CEM T-cell 
lymphoblasts; E/T, effector to target ratio; FCS, fetal calf serum; HBSS, Hanks’ balanced salt solution; 
PBS, phosphate-buffered saline; RBC ox, ox red blood cells; SBSS, Seligmann’s balanced salt solution; 
SRBC, sheep red blood cells; NZW, New Zealand White rabbits; SPA, Staph.-protein A; EA, antibody- 
sensitized erythrocytes; TA, antibody-sensitized tumor cells. 
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human monocytes have been shown to be capable of killing sensitized tumor cells 
in ADCC (17, 20), as well. 
In this investigation, we have examined the cytotoxic potential of rabbit periph- 
eral blood monocytes and alveolar macrophages in ADCC toward both erythrocyte 
and tumor cell targets. The alveolar macrophages were clearly more efficient at 
killing the sensitized tumor cells, while the monocytes were more effective at lysing 
erythrocytes. This effector cell selectivity was directly related to Fc-receptor-me- 
diated binding of the target cells and was dependent on the degree of sensitization 
of the target cells. The differentiation from monocyte to macrophage may, there- 
fore, be accompanied by changes in criteria required for Fc-receptor-mediated 
binding and lysis of antibody-sensitized targets. 
MATERIALS AND METHODS 
Animals 
Normal healthy female 5-kg New Zealand White (NZW) rabbits (Langshaw 
Distributors, Haslett, Mich.) were used as a source of both monocytes and alveolar 
macrophages. Rabbits were maintained in the animal care facility of Simpson 
Memorial Research Institute. Food and water were available ad libitum. No an- 
tibiotics or other drugs were administered. 
Effector Cells 
Monocytes. Rabbit monocytes were isolated from the peripheral blood of a single 
rabbit for each experiment. The blood was collected by venipuncture of the central 
ear artery into 5% EDTA (0.3 ml/10 ml blood). Mononuclear cells were isolated 
by Ficoll-Hypaque density gradient centrifugation (19). Briefly, the blood was 
diluted 1:2 in Seligmann’s balanced salt solution (SBSS), then centrifuged at 115Og 
for 25 min through Ficoll-Hypaque. The mononuclear cells were collected, washed 
twice, and resuspended in SBSS. Monocytes were then isolated from the mono- 
nuclear cell suspension as described by Shaw et al. (20). Briefly, 50 X lo6 mono- 
nuclear cells ( 1 ml) were added to loo-mm tissue culture plates (Corning No. 
25020) containing 10 ml of Hanks’ balanced salt solution (HBSS) supplemented 
with 13% autologous serum. After incubation for 90 min at 37°C in a humidified 
atmosphere of 5% CO* in air, the adherent cell monolayer was washed vigorously 
five times with complete medium consisting of RPM1 1640, 10% heat-inactivated 
fetal calf serum (FCS), 100 U/ml penicillin, and 100 pg/ml streptomycin. After 
washing, the adherent cells were incubated for 2 min in 5 ml of cold 0.2% EDTA 
in physiological saline containing 0.1% bovine serum albumin. The adherent cells 
were harvested by gentle scraping with a rubber policeman, washed twice in com- 
plete medium, and adjusted to the appropriate concentrations (as indicated in the 
text). Cell viability was determined by trypan blue dye exclusion. The adherent 
cell suspension was characterized by morphology (Wright stain), phagocytosis of 
opsinized zymosan (21) and staining for the nonspecific esterase (22) and found 
to be 295% monocytes by these three criteria. Cell viability was 295%. 
Macrophages. Rabbit alveolar macrophages were obtained by pulmonary lavage 
(23). Briefly, rabbits were sacrificed and the lungs dissected free. The lungs were 
filled with 50 ml of HBSS and massaged gently and the cell suspensions aspirated. 
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This procedure was repeated an additional three times. The cell suspensions were 
combined, washed twice in complete medium, and adjusted to the appropriate 
concentrations (as indicated in the text). Viability and purity were assessed as for 
the monocytes. The alveolar macrophages were 295% viable and 295% pure by 
all three criteria. 
Target Cells 
Erythrocytes. Fresh ox erythrocytes (RBCox) (Colorado Serum Company Lab- 
oratories, Denver, Colo.) were washed three times in HBSS and radiolabeled by 
incubating 250 X lo6 cells with 30 &i of NaZ5’Cr04 (New England Nuclear, 
Boston, Mass.) for 60 min at 37°C. The RBCox were then washed two times with 
HBSS and sensitized by incubating 50 X lo6 targets with 50 ~1 of varying dilutions 
of rabbit anti-sheep red blood cell (SRBC) antisera (Cordis Corp., Miami, FL) 
for 45 min and 37°C with gentle agitation every 15 min. The cell concentration 
was adjusted to 2 X 106/ml for use in all ADCC experiments. Radiolabeled RBCox 
incubated with phosphate-buffered saline (PBS) were used as control (nonsensi- 
tized) target cells. 
Tumor cells. A human T-cell lymphoblast cell line (CEM, ref. (24)) was ra- 
diolabeled by incubation of 10 X lo6 cells in 0.3 ml of a Tris-phosphate buffer 
(25) containing 100 &i of NaZ5’Cr04 for 90 min at 37°C with gentle agitation 
every 15 min. The CEM were subsequently washed twice in complete medium and 
sensitized by incubation of 2.5 X lo6 CEM with 50 ~1 of varying dilutions of rabbit 
anti-CEM antisera for 45 min at 37°C with gentle agitation every 15 min. The 
cells were washed two times in complete medium and adjusted to 2 X lO’/ml for 
use in all ADCC experiments. Radiolabeled CEM incubated with PBS were used 
as control (nonsensitized) target cells. 
Antisera 
Rabbit anti-SRBC antiserum (7 S IgG; Cordis Corporation, Miami, Fla.) was 
used at dilutions of 1:2, 1:8, 1:32, and 1: 128 (in PBS) to sensitize the RBCox 
targets. RBCox (instead of SRBC) were used as target cells and sensitized with 
anti-SRBC antisera to avoid the hemagglutination that occurred from the sensi- 
tization of SRBC with homologous antisera [even at dilutions ( 1: 128) which would 
not mediate ADCC]. 
Anti-CEM T-lymphoblast antisera was raised in rabbits as previously described 
(20). The antisera was used undiluted, or at dilutions of 1:8, 1:32 and 1: 128 in 
PBS to sensitize CEM target cells. All antisera were heat inactivated at 56°C for 
30 min prior to use for sensitizing the target cells. 
Antibody-Dependent Cellular Cytotoxicity (ADCC) 
The ability of rabbit monocytes and alveolar macrophages to lyse antibody-sen- 
sitized target cells was determined by a 4-hr “Cr-release assay (20). Briefly, 0.1 
ml of the effector cells (at various concentrations as indicated in the text) was 
mixed with 0.1 ml of the antibody-sensitized RBCox (2 X 106/ml) or CEM (2 
X 105/ml) target cells in 0.3-ml flat-bottom well tissue culture plates (Costar, 
Cambridge, Mass.). The plates were centrifuged for 3 min at 50g to initiate cell- 
362 GARAGIOLA, HUARD, AND LO BUGLIO 
cell contact. Plates were incubated at 37°C for 4 hr in a humidified atmosphere 
of 5% COZ in air. After 4 hr, 100 ~1 of supernatant was aspirated from each well 
to determine the amount of “Cr released. Percentage cytotoxicity was calculated 
by the formula 
% ADCC = (A - B)/(C - B) X 100, 
where (A) = mean counts per minute in supernatants from wells (triplicate) con- 
taining both effector and target cells; (B) = mean counts per minute in supernatants 
from wells containing target cells alone (spontaneous release); and (C) = mean 
counts per minute of the total number of target cells added to each well. Spon- 
taneous release from RBCox was ~6% and from CEM targets ranged from 6 
to 15%. 
Determination of Target Cell Binding 
Effector cell binding of RBC ox was determined by modification of the EA (an- 
tibody-sensitized erythrocyte) rosette formation assay (26) as previously described 
(27). To determine the binding of RBCox, 100 ~1 of purified effector cells ( 10 
X 106/ml) was mixed with an equal volume of the antibody-sensitized target cells 
(250 X 106/ml) and sedimented by centrifugation at 1OOg for 3 min. The cell pellet 
was incubated at an ambient temperature for 15 min and the cells were resuspended 
in their own supernatant. One drop of cell suspension was mixed with one drop of 
0.1% toluidine blue and examined microscopically. Effector cells binding 0, 1-4, 
or 25 sensitized RBCox were enumerated. Duplicate slides were examined and 200 
cells were counted on each slide. 
To determine the effector cell binding of sensitized CEM tumor cell targets, 100 
~1 of purified monocytes or alveolar macrophages (1.0 X lO’/ml) was mixed with 
an equal volume of the antibody-sensitized target cells (2.5 X 106/ml) and sedi- 
mented as described above. After incubation for 15 min the cells were resuspended 
and the cell suspension was stained for the nonspecific esterase to differentiate the 
effector cells from the CEM T-lymphoblast targets. The cell suspension was ex- 
amined microscopically and effector cells binding 0, 1-4, or r5 sensitized CEM 
tumor cells were enumerated. 
Quantitation of Target Cell-Bound IgG 
The amount of antibody (IgG) on the target cell surface was quantitated using 
I*?-radiolabeled protein A (SPA) from Staphylococcus aureus (Cowan I) as pre- 
viously described (28). 
RESULTS 
Monocyte and Macrophage ADCC of Erythrocyte Targets 
We compared monocyte and macrophage ADCC to RBCox targets using (a) 
varying numbers of effector cells, and (b) target cells sensitized with varying di- 
lutions of antisera. As seen in Fig. 1, monocyte ADCC to RBCox was significantly 
higher than macrophage ADCC across a wide range of effector cell concentrations 
(P < 0.05 by t test). Increasing the number of monocytes produced increasing 
MONOCYTE/MACROPHAGE ADCC 363 
40 
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E/T I:1 54 IO:1 2O:l 
FIG. 1. The effect of varying numbers of monocytes (0) and alveolar macrophages (A), on ADCC 
to RBCox targets. Effector cells were incubated with 2 X 10’ RBC ox sensitized with rabbit anti-SRBC 
antisera diluted 1:2 in PBS. The data are presented as the mean percentage “Cr release + SD of 
triplicate values from at least three experiments. Total cpm/2 X IO5 targets was 1800 5 200; spontaneous 
release was 56%. 
ADCC up to an effector cell number that was equivalent to an effecter/target cell 
ratio (E/T) of 10: 1. Increasing the number of macrophages, however, failed to 
elevate the small amount of ADCC against the same target cells. 
To examine the effect of varying the amount of antibody on the target cell 
surface, RBCox were sensitized with varying dilutions of the rabbit anti-SRBC 
antisera ( 1:2 to 1: 128) (Fig. 2). These antisera dilutions produced a range of mol- 
ecules of IgG/target cell of 60,000 to 15,000 as determined by the “‘I-SPA assay. 
Monocyte ADCC exceeded that of the macrophages at all levels of antibody sen- 
sitization of the target cells examined. The degree of monocyte ADCC to RBCox 
I 
I:32 I:126 
RABBIT ANTI-SRBC ANTISERA DILUTION 
FIG. 2. The effect of varying the degree of target cell sensitization on monocyte (a) and alveolar 
macrophage (m) ADCC to RBCox targets. Effector cells were incubated with 2 X 10’ target cells 
at a 2O:l E/T ratio. The data are presented as the mean percentage 5’Cr release + SD of triplicate 
values from at least three experiments. Total cpm/2 X 10’ targets was 1800 f 200; spontaneous release 
was 16%. 
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was dependent upon the degree of antibody sensitization. Neither effector cell 
produced significant lysis of the nonsensitized target cells at any E/T ratio ex- 
amined. 
Monocyte and Macrophage ADCC of Tumor Cell Targets 
In the same experiments, monocytes and macrophages were examined for their 
ability to carry out ADCC to antibody-sensitized tumor cells. As seen in Fig. 3, 
increasing numbers of macrophages produced progressively increasing degrees of 
ADCC while monocytes failed to produce significant ADCC at any of these effector 
cell numbers. This is in marked contrast to the target cell preferences exhibited 
for RBCox, where monocytes were more effective at ADCC. As shown in Fig. 4, 
using dilutions of sensitizing antisera to yield varying levels of IgG/target cell from 
400,000 to 25,000 (by ‘251-SPA assay) revealed that the degree of ADCC by 
macrophages was dependent on the amount of antibody on the target cell surface. 
Monocytes failed to carry out ADCC at any antibody concentration tested. Non- 
sensitized tumor cells were not lysed by either effector cell population. 
We also examined six other rabbit antisera to these target cells for their ability 
to mediate ADCC by monocytes and macrophages. As seen in Table 1, monocytes 
produced little or no ADCC with these antibody-sensitized tumor cells while the 
macrophages produced varying degrees of ADCC depending on the antisera used. 
Monocyte and Macrophage Ability to Bind Antibody-Sensitized Target Cells 
In order to determine whether the differences in effector cell ADCC might be 
related to initial Fc-receptor binding or to a postbinding event, we examined the 
ability of monocytes and macrophages to bind these antibody-sensitized target cells. 
Figure 5 illustrates typical rosettes formed between effector cells and antibody- 
sensitized RBCox (5a) or tumor cells (5b). As seen in Table 2, monocytes were 
NUMBER OF EFFECTOR CELLS xKJ4 
E/T I:1 54 IO:1 204 
FIG. 3. The effect of varying numbers of monocytes (0) and alveolar macrophages (A), on ADCC 
to CEM T-lymphoblast targets. Effector cells were incubated with 2 X lo4 CEM sensitized with undiluted 
antiCEM antisera. The data are presented as the mean percentage “Cr release k SD of triplicate 
values from at least three experiments. Total cpm/2 X lo4 targets was 12,000 +- 2000, spontaneous 
release ranged from 6 to 15%. 




Undiluted 1:32 I :I28 NCUl-WlSitiZed 
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RABBIT ANTI-EM ANTISERA DILUTION 
FIG. 4. The effect of varying the degree of target cell sensitization on monocyte (0) and alveolar 
macrophage (m) ADCC to CEM T-lymphoblast targets. Effector cells were incubated with 2 X 10“ 
target cells at a 2O:l E/T ratio. Data are presented as a mean percentage “Cr release + SD of triplicate 
values from at least three experiments. Total cpm/2 X lo4 targets was 12,000 + 2000, spontaneous 
release ranged from 6 to 15%. 
able to bind antibody-sensitized RBC ox while over 80% of these cells failed to bind 
the antibody-sensitized tumor cells. Conversely, few macrophages were able to bind 
antibody-sensitized RBCox but a majority were able to bind antibody-sensitized 
tumor cells. Thus, the differences seen in terms of lysis of target cells correlated 
well with the ability of the effector cells to recognize and bind the antibody-sen- 
sitized targets. In the absence of antibody, little or no target cell binding was seen 
with either effector cell population. 
DISCUSSION 
The membrane Fc-receptors of monocytes and macrophages have been shown 
to be capable of binding soluble immune complexes, aggregated IgG, and antibody- 
TABLE 1 
Monocyte and Alveolar Macrophage ADCC to CEM Tumor Cells 
Percentage ADCC 
Cell source EITb 1’ 2 3 4 5 6 
Alveolar 20: 1 9 52 35 27 22 16 
macrophage 1O:l 9 54 24 17 12 9 
5:l 4 37 12 9 6 4 
1:l 0 10 2 2 1 1 
Monocyte 20: 1 0 7 1 5 6 1 
lo:1 0 3 0 3 3 1 
5:l 0 1 0 1 1 1 
1:l 0 0 0 0 0 0 
a Percentage ADCC = mean percentage ADCC from triplicate samples. 
b E/T, effector cell:target cell ratio. 
’ l-6 refer to six different rabbit antiCEM T-Lymphoblast antisera preparations. 
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TABLE 2 
Target Cell Binding by Rabbit Monocytes and Alveolar Macropbages 
Target 
cell 
Percentage monocytes binding varying numbers 
of target cellsb 





15 * 3 45 + 5 40 + 9 
96 + 3 4+2 o+o 
83 + 4 16 f 4 1+1 
98 + 2 2k2 Ok0 
Percentage of alveolar macrophages binding varying 
numbers of target cells 
0 l-4 25 
EA 14 + 5 22 ic 3 4f3 
E 91 k 3 3k3 Ok0 
TA 6+2 23 & 3 71 + 5 
T 92 zk 4 7+3 1+1 
’ E indicates control RBC,,; EA indicates RBCox sensitized with a 1:2 dilution of rabbit anti-SRBC 
antisera; T indicates control CEM tumor cells; TA indicates CEM tumor cells sensitized with undiluted 
rabbit antiCEM antisera. 
b Percentage expressed as the mean -+ 1 SD of athree experiments. 
coated target cells (6-9). By this Fc-receptor:antibody interaction, these effector 
cells are also capable of postbinding cytolysis of sensitized target cells in ADCC 
(lo- 16). The expression of Fc-receptor activity may vary with different cell pop- 
ulations. For example, Rhodes (29) has presented evidence that guinea pig peri- 
toneal macrophage subpopulations may vary in avidity of their Fc-receptor for 
immune complexes. Hunninghake and Fauci (18) attempted to compare the ADCC 
capacity of guinea pig alveolar, spleen, and blood mononuclear phagocytes toward 
sensitized chicken red blood cells and Chang liver cells. They noted that alveolar 
macrophages had a cytotoxic capacity against antibody-coated chicken red blood 
cells greater than that of blood monocytes or splenic macrophages. They were 
unable to demonstrate significant ADCC to tumor cells by any of these monocyte- 
macrophage cell populations. No studies were done to examine Fc-receptor binding 
of the target cell preparations. 
In this study, we were interested in comparing the ability of rabbit blood mono- 
cytes and alveolar macrophages from the same animal with regard to their ability 
to bind and lyse two different target cells coated with rabbit antibody. In this way, 
we hoped to gain some insight into potential changes in Fc-receptor-mediated cell 
functions during the transition from monocytes to tissues macrophages. The results 
were surprising in that RBCox coated with adequate rabbit IgG to mediate strong 
monocyte binding and subsequent target cell lysis were not readily recognized or 
lysed by alveolar macrophages. Conversely, CEM tumor cells heavily sensitized by 
rabbit IgG were bound and lysed by alveolar macrophages while serving as poor 
target cells for binding and lysis by blood monocytes. Clearly, the criteria used by 
these two cell populations for membrane Fc-receptor interaction with antibody 
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displayed on a target cell surface had undergone significant modification in the 
maturation process from monocyte to tissue macrophage. Recent studies in our 
laboratory suggest, however, that monocyte Fc-receptor interaction with antibody- 
coated tumor cells can occur following in vivo activation of monocytes with my- 
cobacteria and their active adjuvant component muramyl dipeptide (38-40). 
There have been other examples of effector cells which differ in their criteria 
for membrane Fc-receptor interaction with antibody displayed on target cell sur- 
faces. Human Fc-receptor-positive lymphocytes (K cells) and monocytes appear 
to have membrane Fc-receptors with similar specificities for the IgG, and IgG3 
subclasses of immunoglobulin (30-33). However, these lymphocytes are unable to 
bind and lyse human red cells coated with certain human antisera (anti-D) while 
monocytes from the same donor bind and lyse these target cells well (34). Alteration 
of the distribution of antibody on these red cells (clustering) allows lymphocytes 
to bind and lyse red cell targets when sensitized with the same anti-D antisera 
(28, 34). These studies suggest that antibody distribution represents a criteria for 
lymphocyte Fc-receptor interaction with at least some types of antibody-sensitized 
target cells not shared by the monocyte. In addition, binding of soluble IgG oligo- 
mers appears to be similar by human granulocytes, lymphocytes, and monocytes 
(35). Despite this, ADCC of CEM tumor cells by Fc-receptor-positive human 
granulocytes has been found to require 100 times the concentration of rabbit an- 
tibody on the tumor cell surface than required for either lymphocyte or monocyte 
ADCC (36). Differences in ability to recognize and lyse antibody-coated target 
cells by the same cell populations from different species have been reported (37). 
We have also reported that human monocytes are quite effective at recognition and 
lysis of the same rabbit antibody-coated CEM target cells (20) that failed to elicit 
ADCC by rabbit monocytes in this study. Thus, it would appear that different 
effector cell populations or similar populations of effector cells from different spe- 
cies differ in their criteria for interaction with IgG displayed on target cell surfaces. 
The current study extends these observations by indicating that criteria for Fc- 
receptor interaction with antibody-sensitized target cells can differ dramatically 
at different stages of differentiation in the monocyte/macrophage cell lineage. 
These differences may be related to alteration in Fc-receptor requirements for 
antibody density, distribution, subclass, or other as yet undetermined factors which 
alter the Fc-receptor interaction with the Fc portion of IgG displayed on cell 
surfaces. Further, this study indicates that the variation seen in the sensitivity of 
certain target cells to ADCC by unique effector cell populations can be explained 
at least in part by variation in Fc-receptor binding of target cells rather than 
postbinding events. 
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